D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial

JAMA Psychiatry

Volumn 72, Issue 7, 2015, Pages 659-667

  Andersson, Erik ^a   Hedman, Erik ^a   Enander, Jesper ^a   Djurfeldt, Diana Radu ^a   Ljótsson, Brjánn ^a   Cervenka, Simon ^a   Isung, Josef ^a   Svanborg, Cecilia ^a   Mataix Cols, David ^a   Kaldo, Viktor ^a   Andersson, Gerhard ^a,b   Lindefors, Nils ^a   Rück, Christian ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOSERINE; PLACEBO; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNET; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE; AGED; AGONISTS; COMPARATIVE STUDY; COMPUTER ASSISTED THERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBSESSIVE-COMPULSIVE DISORDER; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CYCLOSERINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; RECEPTORS, N-METHYL-D-ASPARTATE; THERAPY, COMPUTER-ASSISTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84932604863     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.0546     Document Type: Article

References (40)

1. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessivecompulsive disorder. Am J Psychiatry. 2005;162(1): 151-161.
2. Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitivebehavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165(5):621-630.
3. Romanelli RJ, Wu FM, Gamba R, Mojtabai R, Segal JB. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials. Depress Anxiety. 2014;31(8):641-652.
4. Ressler KJ, Rothbaum BO. Augmenting obsessive-compulsive disorder treatment: from brain tomind. JAMA Psychiatry. 2013;70(11):1129-1131.
5. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60(4):369-375.
6. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374 (9688):491-499.
7. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62(8):835-838.
8. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):335-341.
9. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(4): 230-237.
10. Mataix-Cols D, Turner C, Monzani B, et al. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br J Psychiatry. 2014;204(1):77-78.
11. Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010;68(11):1073-1076.
12. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-1126.
13. Smits JA, Rosenfield D, Otto MW, et al. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013;47 (10):1455-1461.
14. Smits JA, Rosenfield D, Otto MW, et al. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry. 2013;73(11):1054-1058.
15. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol. 1999;375(1-3):31-40.
16. Werner-Seidler A, Richardson R. Effects of D-cycloserine on extinction: consequences of prior exposure to imipramine. Biol Psychiatry. 2007;62 (10):1195-1197.
17. Difede J, Cukor J, Wyka K, et al. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology. 2014;39(5):1052-1058.
18. Andersson E, Ljótsson B, Hedman E, et al. Internet-based cognitive behavior therapy for obsessive compulsive disorder: a pilot study. BMC Psychiatry. 2011;11:125.
19. Andersson E, Enander J, Andrén P, et al. Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial. Psychol Med. 2012;42(10):2193-2203.
20. Andersson E, Steneby S, Karlsson K, et al. Long-term efficacy of Internet-based cognitive behavior therapy for obsessive-compulsive disorder with or without booster: a randomized controlled trial. Psychol Med. 2014;44(13):2877-2887.
21. Waller G. Evidence-based treatment and therapist drift. Behav Res Ther. 2009;47(2):119-127.
22. Andersson G, Titov N. Advantages and limitations of Internet-based interventions for common mental disorders. World Psychiatry. 2014; 13(1):4-11.
23. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (Swedish Version). Danderyd, Sweden: Pilgrim Press; 1999.
24. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
25. Farmer KC.Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21 (6):1074-1090.
26. Hajebi A, Motevalian A, Amin-Esmaeili M, et al. Telephone versus face-to-face administration of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, for diagnosis of psychotic disorders. Compr Psychiatry. 2012;53(5):579-583.
27. Baer L, BlaisMA. Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. New York, NY: Humana; 2010.
28. GuyW, ed. Clinical Global Impressions. Rockville, MD: US Dept of Health & Human Services; 1976.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Association; 2000.
30. Steketee G, Frost R, Bogart K. The Yale-Brown Obsessive Compulsive Scale: interview versus self-report. Behav Res Ther. 1996;34(8):675-684.
31. Foa EB, Huppert JD, Leiberg S, et al. The Obsessive-Compulsive Inventory: development and validation of a short version. Psychol Assess. 2002; 14(4):485-496.
32. Svanborg P, Åsberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand. 1994;89(1):21-28.
33. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
34. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer; 2009.
35. Farris SG, McLean CP, Van Meter PE, Simpson HB, Foa EB. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry. 2013;74(7):685-690.
36. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(2):269-276.
37. Hofmann SG, Smits JA, Rosenfield D, et al. D-cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013;170(7):751-758.
38. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res. 2007;41(6):466-471.
39. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298-304.
40. Burghardt NS, Sigurdsson T, Gorman JM, McEwen BS, LeDoux JE. Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry. 2013;73(11):1078-1086.